【光大医药&海外】药明生物:临床前收入快速恢复,整体项目数稳步提升

EBoversea
29 Mar

报告标题:《临床前收入快速恢复,整体项目数稳步提升——药明生物(2269.HK)2024年年报点评》报告发布日期:2025年3月26日分析师:王明瑞(执业证书编号:S0930520080004)分析师:叶思奥(执业证书编号:S0930523050003)往期回顾【光大医药&海外】港股医药:关注低估值高成长投资机会,建议积极增加板块配置【光大医药&海外】药明康德(A+H):TIDES业务高速增长,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10